Ownership Action Alert: Mallinckrodt PLC (NYSE:MNK) Institutional Investors Sentiment Index Flat in Q2 2016

November 28, 2016 - By Linda Rogers   ·   0 Comments

Ownership Action Alert: Mallinckrodt PLC (NYSE:MNK) Institutional Investors Sentiment Index Flat in  Q2 2016

Sentiment for Mallinckrodt PLC (NYSE:MNK)

Mallinckrodt PLC (NYSE:MNK) institutional sentiment increased to 0.91 in 2016 Q2. Its up 0.08, from 0.83 in 2016Q1. The ratio has increased, as 158 investment professionals increased and started new holdings, while 191 sold and decreased stakes in Mallinckrodt PLC. The investment professionals in our partner’s database now own: 100.83 million shares, down from 105.38 million shares in 2016Q1. Also, the number of investment professionals holding Mallinckrodt PLC in their top 10 holdings increased from 5 to 7 for an increase of 2. Sold All: 45 Reduced: 146 Increased: 113 New Position: 45.

Mallinckrodt public limited company is engaged in the specialty pharmaceuticals and nuclear imaging business. The company has a market cap of $6.15 billion. The Firm develops, makes, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. It has a 12.46 P/E ratio. The Company’s divisions include Specialty Brands, Specialty Generics and Nuclear Imaging.

About 327,255 shares traded hands. Mallinckrodt PLC (NYSE:MNK) has declined 10.73% since April 25, 2016 and is downtrending. It has underperformed by 16.75% the S&P500.

Analysts await Mallinckrodt PLC (NYSE:MNK) to report earnings on November, 29 before the open. They expect $1.99 earnings per share, up 8.15% or $0.15 from last year’s $1.84 per share. MNK’s profit will be $215.66M for 7.13 P/E if the $1.99 EPS becomes a reality. After $2.20 actual earnings per share reported by Mallinckrodt PLC for the previous quarter, Wall Street now forecasts -9.55% negative EPS growth.

According to Zacks Investment Research, “Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.”

Consonance Capital Management Lp holds 13.42% of its portfolio in Mallinckrodt PLC for 1.56 million shares. Endurant Capital Management Lp owns 234,729 shares or 4.77% of their US portfolio. Moreover, Bridger Management Llc has 4.66% invested in the company for 1.19 million shares. The Oregon-based Peregrine Asset Advisers Inc. has invested 4.1% in the stock. Broadwood Capital Inc, a New York-based fund reported 322,411 shares.#img1#

Mallinckrodt PLC (NYSE:MNK) Ratings Coverage

Ratings analysis reveals 81% of Mallinckrodt’s analysts are positive. Out of 16 Wall Street analysts rating Mallinckrodt, 13 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $72 while the high is $218. The stock’s average target of $104 is 83.26% above today’s ($56.75) share price. MNK was included in 33 notes of analysts from August 5, 2015. Deutsche Bank maintained Mallinckrodt PLC (NYSE:MNK) on Wednesday, October 7 with “Buy” rating. Northland Capital initiated the stock with “Outperform” rating in Wednesday, October 14 report. RBC Capital Markets maintained Mallinckrodt PLC (NYSE:MNK) rating on Monday, March 28. RBC Capital Markets has “Outperform” rating and $218 price target. As per Wednesday, November 11, the company rating was initiated by Northland Capital. The firm has “Buy” rating given on Friday, August 12 by Stifel Nicolaus. The company was maintained on Thursday, September 24 by Barclays Capital. The firm earned “Overweight” rating on Thursday, December 3 by Morgan Stanley. BMO Capital Markets initiated the shares of MNK in a report on Wednesday, June 29 with “Outperform” rating. The stock has “Overweight” rating given by Barclays Capital on Thursday, August 25. Barclays Capital maintained it with “Overweight” rating and $135.0 target price in Wednesday, August 5 report.

More news for Mallinckrodt PLC (NYSE:MNK) were recently published by: Investorplace.com, which released: “Why Lowe’s Companies, Inc. (LOW), PDL BioPharma Inc (PDLI) and Mallinckrodt …” on November 16, 2016. Cnbc.com‘s article titled: “Mallinckrodt shares tank as short-seller Andrew Left claims CEO commits fraud” and published on November 16, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Linda Rogers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>